The present invention relates to a method for producing a vitamin- and protein-rich product, to a food product containing the vitamin- and protein-rich product, and to a nutrient medium appropriate for said method on the basis of agricultural tributaries or food tributaries.

The application discloses Lactobacillus strains having a beneficial effect on the metabolic health on a mammalian subject. Further disclosed is compositions comprising such strains and the use thereof for improving the metabolic health or for lowering the blood glucose level in a mammalian subject.

The application discloses Lactobacillus strains having a beneficial effect on the metabolic health on a mammalian subject. Further disclosed is compositions comprising such strains and the use thereof for improving the metabolic health or for lowering the blood glucose level in a mammalian subject.

In certain aspects, described herein are methods, bacteria, and compositions for the treatment of bacterial infections. Specifically, bacteria that can upregulate antimicrobial peptides, e.g., Reg3, within a subject have been identified and methods of using such bacteria to treat infections is described.

Embodiments of the disclosure concern methods and compositions related to manipulation of the microbiome in an individual having at least one social behavior deficit. In particular embodiments, an individual has at least one social behavior deficit and was born from a mother who during pregnancy was obese, overweight, or on a high-fat diet during pregnancy or carries mutations associated with neurodevelopmental disorders. In specific embodiments, the individual having at least one social behavior deficit is provided an effective amount of Lactobacillus reuteri for the improvement of at least one symptom of a social behavior deficit.

The invention concerns Lactobacillus reuteri for use in the prevention or treatment of microbiota dysbiosis, in particular, decreased levels of Actinobacteria and increased levels of Proteobacteria, in young mammals and in the prevention or treatment of disorders associated therewith. The microbiota dysbiosis may have been cause by numerous factors including being born by caesarean section, exposure to antibiotics in utero or after birth, or, parenteral feeding, hospitalizing, psychological stress or by gastrointestinal dysfunctions. The disorders that may be treated or prevented by preventing or treating microbiota dysbiosis include propensity to infection, allergy, type I diabetes mellitus, insulin resistance, type 2 diabetes, celiac disease, peripheral and central adiposity, obesity, necrotizing enterocolitis, inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, and functional gastrointestinal disorders such as IBS, functional diarrhea, functional constipation, recurrent abdominal pain, and dyspepsia.

A probiotic for inhibiting growth of Proteus mirabilis, including a microorganism selected from the group consisting of Lactobacillus rhamnosus, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus reuteri, Bifidobacterium animalis subsp. lactis, Bifidobacterium infantis, Bifidobacterium bifidum and a combination thereof. A fermentation broth and an application of the probiotic are further provided.

The invention relates to probiotic compositions, sachets, and nutritional supplements comprising a probiotic bacterium capable of an adaptive response resulting from growth in the presence of pomegranate extract, as well as methods of selecting, producing, and using thereof.

The disclosure discloses application of breast milk-derived Lactobacillus reuteri in regulating the maternal and infant immune function, belonging to the fields of microbiological technology and food science. The disclosure provides the effects of Lactobacillus reuteri Fn041 in enhancing the immunity of pregnant or lactating women and infants, i.e., enhancing the mucosal barrier, promoting the production of intestinal antibacterial peptides and IgA, promoting the development of the immune system of infants, preventing pathogen infection and reducing the incidence of allergic diseases.

The disclosure discloses application of breast milk-derived Lactobacillus reuteri in regulating the maternal and infant immune function, belonging to the fields of microbiological technology and food science. The disclosure provides the effects of Lactobacillus reuteri Fn041 in enhancing the immunity of pregnant or lactating women and infants, i.e., enhancing the mucosal barrier, promoting the production of intestinal antibacterial peptides and IgA, promoting the development of the immune system of infants, preventing pathogen infection and reducing the incidence of allergic diseases.